Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2023-06-07 Regulatory Filings
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
신규시설투자등(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a new facility investment (capital expenditure) by its subsidiary, Daewoong Bio. It details the investment amount, purpose, and timeline. Since it describes a specific corporate investment project rather than a general report announcement, dividend, or share transaction, it falls under the 'Regulatory Filings' category as a general corporate disclosure.
2023-06-07 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding the termination of a licensing agreement for their drug 'Fexuprazan'. It details the nature of the contract, the reason for termination (strategic change by the partner), and future business implications. Since this is a specific corporate announcement regarding a material business event (licensing agreement termination) that does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing (RNS).
2023-06-05 Korean
기업지배구조보고서공시
Governance Information Classification · 100% confidence The document is a short announcement (1015 characters) titled 'Corporate Governance Report Disclosure' which explicitly states that the detailed report is attached. According to the 'Menu vs Meal' rule, an announcement of a report that directs the reader to an attachment is classified as a Report Publication Announcement (RPA).
2023-05-31 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Daewoong' (주)대웅, covering the period from January 1, 2023, to March 31, 2023. It contains detailed business descriptions, product information, production capacity, and financial data, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
신규시설투자등(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a new facility investment (Nabota Plant 3 construction). It details the investment amount, purpose, timeline, and board approval status. Since this is a specific announcement of a capital expenditure/investment project rather than a general report or financial statement, it falls under the category of regulatory filings for corporate events.
2023-05-02 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
M&A Activity Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a 'Technology Transfer Agreement' (licensing deal) for a drug candidate (DWP213388). It details the contract terms, financial milestones, and the nature of the partnership with Vitalli Bio, Inc. This type of disclosure regarding significant business contracts, licensing, or strategic partnerships is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A or capital raising.
2023-04-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.